Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for advanced liver cancer: drug duo tested in phase 2 trial

NCT ID NCT05257590

First seen Jan 06, 2026 · Last updated May 19, 2026 · Updated 25 times

Summary

This study tests a new experimental drug called CVM-1118 combined with the immunotherapy nivolumab in people with advanced liver cancer that cannot be removed by surgery. About 95 adults will receive the combination to see if it shrinks tumors and how long any benefit lasts. The goal is to find a better treatment option for this hard-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kaohsiung Chang Gung Memorial Hospital

    RECRUITING

    Kaohsiung City, Taiwan

    Contact

  • Keelung Chang Gung Memorial Hospital

    RECRUITING

    Keelung, Taiwan

    Contact

  • National Cheng Kung University Hospital

    RECRUITING

    Tainan, Taiwan

    Contact

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 100, Taiwan

    Contact

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 112, Taiwan

    Contact

Conditions

Explore the condition pages connected to this study.